Ninety percent of therapeutic agents reaching clinical trial fail to reach entry to market, with safety concerns being a major cause for failures in phase I and II clinical trials. Drug-induced liver ...
This article is based on a poster originally authored by Yassen Abbas, Hailey Sze, Christiana Skarlatopoulou, Ashley A. Spreen, Elizabeth M. Boazak, William R. Thelin, and Tomasz Kostrzewski which was ...
For those considering adding Organ-on-a-chip (OOC) technology into the workflow, it may be unclear where to start. Firstly, using a commercially available solution, such as CN Bio's PhysioMimix ®, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback